Hormone Therapy Safety: What the Labeling Actually Says
Hormone therapy is neither the danger it was portrayed as nor risk-free. The honest version is nuanced and individual.
By Hypergevity Editorial Team · Published September 3, 2026 · Updated September 3, 2026 · 8 min read
- FDA labeling for menopausal hormone therapy carries boxed warnings that vary by product and formulation.
- Risk and benefit differ by age, years since menopause, formulation, route and dose.
- Certain histories — including some cancers, blood clots and stroke — generally rule out systemic therapy.
- Compounded 'bioidentical' pellets and custom blends are not FDA-approved products.
- Decisions belong in a documented conversation with a licensed clinician who knows your history.
Public understanding of hormone therapy swung from routine prescribing to widespread avoidance and, more recently, to enthusiastic marketing. None of those extremes reflects the labeling or the clinical nuance.
What the FDA-approved labeling warns about
Boxed warnings on menopausal hormone therapy products address risks including endometrial cancer with unopposed estrogen, cardiovascular disorders such as stroke and blood clots, probable dementia risk in older postmenopausal users, and breast cancer risk with estrogen plus progestin. The specific warning text depends on the product and formulation, which is why reading your own product's labeling matters.
They exist to make prescribing individual — the right candidate, the right formulation, the lowest effective dose, and periodic reassessment — not to ban the medication class.
Who is generally not a candidate for systemic therapy
- Known, suspected or history of breast cancer, or estrogen-dependent cancer
- Undiagnosed abnormal genital bleeding
- Active or prior history of blood clots in the legs or lungs, or arterial thromboembolic disease
- Active liver disease
- Known pregnancy
This list is illustrative rather than exhaustive; your clinician screens against your full history and the specific product.
Why timing and formulation matter
| Variable | Why it changes the calculation |
|---|---|
| Age and years since menopause | The risk-benefit balance differs for early versus late initiation |
| Route | Transdermal and oral routes differ in some risk profiles |
| Dose | The lowest effective dose is the standard approach |
| Uterus status | Estrogen without a progestogen raises endometrial cancer risk in people with a uterus |
| Local versus systemic | Local vaginal therapy has minimal systemic absorption |
On compounded pellets and 'bioidentical' blends
Marketing often positions these as natural and safer. They are not FDA-approved, dosing consistency is not guaranteed, and pellets cannot be removed easily if a problem develops. FDA-approved products include options many people would describe as bioidentical, without the compounding uncertainty.
Frequently asked questions
- Does hormone therapy cause breast cancer?
- Labeling for estrogen-plus-progestin therapy describes an increased risk of breast cancer. Magnitude depends on formulation, duration and individual factors — a discussion to have with your clinician using your own history.
- Are compounded bioidentical hormones safer?
- There is no evidence that compounded products are safer, and they are not FDA-approved. FDA-approved options should generally be considered first.
- Can I stay on hormone therapy indefinitely?
- Duration is individualised and reassessed periodically with your clinician.
Have your candidacy reviewed properly
A licensed U.S. provider reviews your medical history against the labeling and contraindications before any prescription is issued.
References
- Hormone Replacement Therapy — MedlinePlus, U.S. National Library of Medicine
- Menopause: Medicines to Help You — U.S. Food and Drug Administration
- Menopause — MedlinePlus, U.S. National Library of Medicine
Prescription products require an online consultation with a healthcare professional who will determine if a prescription is appropriate. You will be notified through email, text/SMS, or your online Hypergevity portal if approved. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness. If receiving treatment for other conditions, your provider may prescribe FDA-approved generic or brand prescription drugs. If you are unsure, always ask your provider which medication they are prescribing.